News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
683,348 Results
Type
Article (38969)
Company Profile (276)
Press Release (644103)
Section
Business (203823)
Career Advice (1985)
Deals (35357)
Drug Delivery (84)
Drug Development (80770)
Employer Resources (168)
FDA (16085)
Job Trends (14797)
News (344465)
Policy (32429)
Tag
Academia (2530)
Alliances (49035)
Alzheimer's disease (1215)
Approvals (16004)
Artificial intelligence (116)
Bankruptcy (352)
Best Places to Work (11465)
Biotechnology (196)
Breast cancer (107)
Cancer (905)
Cardiovascular disease (81)
Career advice (1656)
Cell therapy (199)
Clinical research (63927)
Collaboration (326)
Compensation (168)
COVID-19 (2522)
Cystic fibrosis (78)
Data (862)
Diabetes (134)
Diagnostics (6096)
Earnings (84166)
Employer resources (146)
Events (108887)
Executive appointments (248)
FDA (16529)
Funding (289)
Gene therapy (149)
GLP-1 (558)
Government (4318)
Healthcare (18654)
Infectious disease (2597)
Inflammatory bowel disease (102)
Interviews (308)
IPO (16271)
Job creations (3622)
Job search strategy (1415)
Layoffs (408)
Legal (7848)
Lung cancer (155)
Manufacturing (151)
Medical device (13147)
Medtech (13152)
Mergers & acquisitions (19108)
Metabolic disorders (364)
Neuroscience (1456)
NextGen Class of 2024 (6496)
Non-profit (4462)
Northern California (1212)
Obesity (216)
Opinion (176)
Patents (94)
People (56128)
Phase I (19828)
Phase II (28147)
Phase III (21015)
Pipeline (212)
Postmarket research (2553)
Preclinical (8430)
Radiopharmaceuticals (234)
Rare diseases (180)
Real estate (5888)
Regulatory (21441)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1083)
Startups (3560)
United States (11698)
Vaccines (537)
Weight loss (160)
Date
Today (282)
Last 7 days (832)
Last 30 days (2957)
Last 365 days (35723)
2024 (30454)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27329)
Location
Africa (713)
Arizona (187)
Asia (37012)
Australia (6037)
California (2738)
Canada (1178)
China (209)
Colorado (119)
Connecticut (122)
Europe (79242)
Florida (396)
Georgia (100)
Illinois (308)
Indiana (179)
Kansas (95)
Maryland (515)
Massachusetts (2245)
Michigan (143)
Minnesota (250)
New Jersey (829)
New York (841)
North Carolina (665)
Northern California (1212)
Ohio (127)
Pennsylvania (747)
South America (1091)
Southern California (1083)
Texas (384)
Utah (80)
Washington State (323)
683,348 Results for "medicure inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Medicure Announces Signing of Asset Purchase Agreement with CanAm Bioresearch Inc. for Acquisition of Intellectual Property
Medicure Inc. announces it has signed an asset purchase agreement with CanAm Bioresearch Inc. for the acquisition of the patent and intellectual property related to the discovery of new chemical entities that can be developed for therapeutic use.
June 24, 2024
·
9 min read
Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency
Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH)(OTC PINK:MCUJF) announced today that through its subsidiary, Medicure International Inc., the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for MC-1, an investigational product for the prevention or treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency.
April 23, 2024
·
5 min read
Business
Medicure Reports Financial Results for Quarter Ended March 31, 2024 and Annual General Meeting Director Election Results
Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended March 31, 2024.
May 29, 2024
·
12 min read
Business
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2023
Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH)(OTCPINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter and year ended December 31, 2023.
April 8, 2024
·
12 min read
Business
Medicure To Present Financial Results on April 9, 2024 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2023
Medicure Inc., a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2023 Year End Financial Results on a Conference Call on April 9, 2024 at 8:30 am Eastern Time.
April 4, 2024
·
5 min read
Press Releases
Medicure Reports Financial Results for Quarter Ended June 30, 2024
August 15, 2024
·
11 min read
Press Releases
Medicure Announces Closing of Asset Purchase Agreement with Canam Bioresearch for Acquisition of Intellectual Property
August 15, 2024
·
9 min read
Business
Medicure Reports Financial Results for Quarter Ended September 30, 2023
Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended September 30, 2023.
November 21, 2023
·
12 min read
Business
Medicure Reports Financial Results For Quarter Ended June 30, 2023
Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended June 30, 2023.
July 28, 2023
·
12 min read
Drug Development
Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease
Medicure Inc. announced that the FDA provides complete approval to enroll patients in its pivotal Phase 3 clinical trial to evaluate the use of its investigational product MC-1 for treatment of a rare pediatric disease called pyridoxine 5′-phosphate oxidase deficiency.
November 23, 2023
·
6 min read
1 of 68,335
Next